Literature DB >> 24294504

New possibilities and potential benefits for local control in locally recurrent pancreatic cancer.

Shane Lloyd1, Bryan W Chang.   

Abstract

Entities:  

Year:  2013        PMID： 24294504      PMCID： PMC3819773          DOI： 10.3978/j.issn.2078-6891.2013.049

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


× No keyword cloud information.
  20 in total

1.  Pancreatic cancer in the general population: Improvements in survival over the last decade.

Authors:  Taylor S Riall; William H Nealon; James S Goodwin; Dong Zhang; Yong-Fang Kuo; Courtney M Townsend; Jean L Freeman
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

2.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

Review 3.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.

Authors:  M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

4.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

5.  Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma.

Authors:  Morten Hoyer; Henrik Roed; Lisa Sengelov; Anders Traberg; Lars Ohlhuis; Jorgen Pedersen; Hanne Nellemann; Anne Kiil Berthelsen; Frey Eberholst; Svend Aage Engelholm; Hans von der Maase
Journal:  Radiother Oncol       Date:  2005-07       Impact factor: 6.280

6.  Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas.

Authors:  Jean-Claude M Rwigema; Simul D Parikh; Dwight E Heron; Michael Howell; Herbert Zeh; A James Moser; Nathan Bahary; Annette Quinn; Steven A Burton
Journal:  Am J Clin Oncol       Date:  2011-02       Impact factor: 2.339

7.  Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.

Authors:  Florence Huguet; Thierry André; Pascal Hammel; Pascal Artru; Jacques Balosso; Frédéric Selle; Elisabeth Deniaud-Alexandre; Philippe Ruszniewski; Emmanuel Touboul; Roberto Labianca; Aimery de Gramont; Christophe Louvet
Journal:  J Clin Oncol       Date:  2007-01-20       Impact factor: 44.544

8.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Authors:  Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

9.  A comparison of three treatment strategies for locally advanced and borderline resectable pancreatic cancer.

Authors:  Shane Lloyd; Bryan W Chang
Journal:  J Gastrointest Oncol       Date:  2013-06

10.  Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas.

Authors:  Chris E Lominska; Keith Unger; Nadim M Nasr; Nadim Haddad; Greg Gagnon
Journal:  Radiat Oncol       Date:  2012-05-18       Impact factor: 3.481
View more
  2 in total

1.  FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro.

Authors:  A Allam Mohamed; Andreas Thomsen; Marie Follo; Costantinos Zamboglou; Peter Bronsert; Hanan Mostafa; Aber Amen; Mohamed Mekawy; Anca L Grosu; Thomas B Brunner
Journal:  Strahlenther Onkol       Date:  2020-07-23       Impact factor: 3.621

2.  The Feasibility of Stereotactic Body Proton Beam Therapy for Pancreatic Cancer.

Authors:  Hyunju Shin; Jeong Il Yu; Hee Chul Park; Gyu Sang Yoo; Sungkoo Cho; Joon Oh Park; Kyu Taek Lee; Kwang Hyuck Lee; Jong Kyun Lee; Joo Kyung Park; Jin Seok Heo; In Woong Han; Sang Hyun Shin
Journal:  Cancers (Basel)       Date:  2022-09-20       Impact factor: 6.575
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.